Status:
TERMINATED
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
Lead Sponsor:
Pfizer
Conditions:
Hyperlipoproteinemia Type III
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically k...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Diagnosis of Familial Dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia)
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00145431
Start Date
March 1 2005
End Date
December 1 2006
Last Update
February 17 2012
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anaheim, California, United States, 92804
2
Pfizer Investigational Site
Huntington Beach, California, United States, 92648
3
Pfizer Investigational Site
Orange, California, United States, 92868
4
Pfizer Investigational Site
Pacific Palisades, California, United States, 90272